Eugene

[email protected]

LATEST

Lannett Appoints New CEO
By

By
Lannett, a Philadelphia-headquartered generic drug manufacturer, has appointed Timothy C. Crew as the company’s chief executive officer (CEO), effective January 2, 2018.  The board of directors intends to appoint Crew…

Eloxx Pharmaceuticals Hires New CEO
By

By
Eloxx Pharmaceuticals, a Waltham, Massachusetts-based clinical-stage biopharmaceutical company, has appointed Robert Ward as chairman of the board of directors of Eloxx and chief executive officer (CEO), effective December 27, 2017. …

ANI Acquires Marketing Rights from AstraZeneca for $46.5 Million
By

By
ANI Pharmaceuticals, a Baudette, Minnesota-headquartered pharmaceutical company, has acquired the new drug applications (NDA) and US rights to market four drugs from AstraZeneca for $46.5 million consisting of cash, royalties,…

Peregrine Announces New President and Chief Executive Officer
By

By
Peregrine Pharmaceuticals, a Tustin, California-headquartered biopharmaceutical company, has appointed Roger J. Lias, PhD, as the company’s new president and chief executive officer. Lias, who has more than 20 years of…

Shire Files for FDA Approval for New Plasma Manufacturing Facility
By

By
Shire has filed for approval with the US Food and Drug Administration (FDA) for a new plasma manufacturing facility in Covington, Georgia. The facility, which will support the company’s growing…

Otsuka, X-Chem in Research and Licensing Pact
By

By
Otsuka Pharmaceutical and X-Chem, a Waltham, Massachusetts-headquartered biotechnology company, have signed a research agreement to advance the discovery process for new Otsuka drug compounds. Under the agreement, X-Chem will use…

Janssen Partners for CAR-T Therapies
By

By
Janssen Biotech, one of the pharmaceutical companies of Johnson & Johnson, has signed an agreement with Legend Biotech USA and Legend Biotech Ireland, subsidiaries of Genscript Biotech Corporation, a Hong…

FDA Issues Warning Letter to Fresenius Kabi for Indian Manufacturing Plant
By

By
The US Food and Drug Administration (FDA) has issued a Warning Letter (dated December 18, 2017) for cGMP violations for finished pharmaceuticals to Fresenius Kabi, a Lake Zurich, Illinois-headquartered specialty…

Apotex’s Solid-Dosage Manufacturing Plant in India Cited for GMP Violations
By

By
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued to Apotex, a generic-drug company, a statement of non-compliance with good manufacturing practice (GMPs) for its solid-dosage manufacturing facility…

Pfizer, Arvinas in $830-Million Pact for Protein Degradation Drug Candidates
By

By
Pfizer and Arvinas, a New Haven, Connecticut-headquartered biotechnology company focused on developing based on protein degradation, have signed an agreement worth up to $830 million for developing drug candidates using…